Literature DB >> 5365949

An improved and simplified method of detecting the acetylator phenotype.

D A Evans.   

Abstract

Mesh：

Substances：

Year:  1969        PMID： 5365949      PMCID： PMC1468783          DOI： 10.1136/jmg.6.4.405

Source DB:  PubMed          Journal:  J Med Genet        ISSN： 0022-2593            Impact factor:   6.318


× No keyword cloud information.
  7 in total

1.  HUMAN ACETYLATION POLYMORPHISM.

Authors:  D A EVANS; T A WHITE
Journal:  J Lab Clin Med       Date:  1964-03

2.  FURTHER OBSERVATIONS ON TRIMODALITY OF FREQUENCY DISTRIBUTION CURVE OF BIOLOGICALLY ACTIVE ISONIAZID BLOOD LEVELS AND "CLINE" INFREQUENCIES OF ALLELES CONTROLLING ISONIAZID INACTIVATION.

Authors:  S SUNAHARA; M URANO; H T LIN; T J CHEG; A JARUMILINDA
Journal:  Acta Tuberc Pneumol Scand       Date:  1963

3.  THE RELATIONSHIP BETWEEN THE CAPACITIES OF HUMAN SUBJECTS TO ACETYLATE ISONIAZID, SULFANILAMIDE AND SULFAMETHAZINE.

Authors:  J H PETERS; G R GORDON; P BROWN
Journal:  Life Sci (1962)       Date:  1965-01

4.  Imperfection: biochemical phobias and metabolic ambivalence.

Authors:  D L DRABKIN
Journal:  Perspect Biol Med       Date:  1959       Impact factor: 1.416

5.  Genetic control of isoniazid metabolism in man.

Authors:  D A EVANS; K A MANLEY; V A McKUSICK
Journal:  Br Med J       Date:  1960-08-13

6.  The actylation of sulamethazine and sulfamethoxypyridazine by human subjects.

Authors:  T A White; D A Evans
Journal:  Clin Pharmacol Ther       Date:  1968 Jan-Feb       Impact factor: 6.875

7.  Studies on the metabolic basis for the genetically determined capacities for isoniazid inactivation in man.

Authors:  J H Peters; K S Miller; P Brown
Journal:  J Pharmacol Exp Ther       Date:  1965-11       Impact factor: 4.030
  7 in total
  104 in total

1.  Plasma and salivary concentrations of isoniazid in man: preliminary findings in two slow acetylator subjects.

Authors:  H G Boxenbaum; I Berkersky; V Mattaliano; S A Kaplan
Journal:  J Pharmacokinet Biopharm       Date:  1975-12

2.  Prediction of chronic liver diseases on the basis of the N-acetyltransferase 2 phenotype.

Authors:  L A Piruzyan; I B Korshunov; N V Morozova; N E Pyn'ko; L A Radkevich
Journal:  Dokl Biochem Biophys       Date:  2004 Mar-Apr       Impact factor: 0.788

3.  Two-stage penetration of a single oral dose of sulphadimethoxine into skin blister fluid.

Authors:  A Nowak; A Klimowicz
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

4.  The search for biochemical predictors of the NAT2 phenotype to optimize prophylaxis and pharmacotherapy of hepatic cirrhosis.

Authors:  L A Radkevich; I B Korshunov; N E Pyn'ko; N V Morozova; E V Markarova; D S Nechaev; L A Piruzyan
Journal:  Dokl Biochem Biophys       Date:  2005 Jan-Feb       Impact factor: 0.788

5.  The relationship between the NAT2 phenotype polymorphism and predisposition to suicide in ethnic populations.

Authors:  L A Radkevich; K S Gyul'azizova; I S Nikolaeva; D S Nechaev; I S Soshinskii; E N Krylov; L A Piruzyan
Journal:  Dokl Biochem Biophys       Date:  2005 Sep-Oct       Impact factor: 0.788

Review 6.  Ethnic differences in drug disposition and responsiveness.

Authors:  A J Wood; H H Zhou
Journal:  Clin Pharmacokinet       Date:  1991-05       Impact factor: 6.447

Review 7.  Survey of the human acetylator polymorphism in spontaneous disorders.

Authors:  D A Evans
Journal:  J Med Genet       Date:  1984-08       Impact factor: 6.318

8.  Simultaneous analysis of dapsone and monoacetyldapsone employing high performance liquid chromatography: a rapid method for determination of acetylator phenotype.

Authors:  K Carr; J A Oates; A S Nies; R L Woosley
Journal:  Br J Clin Pharmacol       Date:  1978-11       Impact factor: 4.335

9.  The pharmacokinetics of slow-release procainamide.

Authors:  W J Tilstone; D H Lawson; W Campbell; I Hutton; T D Lawrie
Journal:  Eur J Clin Pharmacol       Date:  1978-12-01       Impact factor: 2.953

10.  Further evidence for an acetylator phenotype difference in the metabolism of hydralazine in man.

Authors:  V Facchini; J A Timbrell
Journal:  Br J Clin Pharmacol       Date:  1981-04       Impact factor: 4.335
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.